BTIG Believes VCYT Won’t Stop Here

By Jason Carr

BTIG analyst Karen Koski reiterated a Buy rating on Veracyte (NASDAQ: VCYT) on March 7 and set a price target of $12. The company’s shares closed yesterday at $9.15, close to its 52-week high of $9.37.

According to, Koski is a 5-star analyst with an average return of 12.9% and a 66.7% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

Currently, the analyst consensus on Veracyte is Moderate Buy and the average price target is $12, representing a 31.1% upside.

In a report issued on February 21, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.

The company has a one year high of $9.37 and a one year low of $4.21. Currently, Veracyte has an average volume of 144.4K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VCYT in relation to earlier this year. Most recently, in June 2016, Bonnie Anderson, the President & CEO of VCYT bought 5,000 shares for a total of $26,950.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Veracyte, Inc. is a molecular diagnostics company which uses novel genomics to resolve the critical healthcare problem of diagnostic ambiguity. The company discovers, develops and commercializes molecular diagnostic solutions that enable physicians to make more informed treatment decisions early. Veracyte was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.